These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8440577)

  • 1. [What forms of thromboembolism prevention and therapy can be used in patients with chronic inflammatory bowel diseases?].
    Seifried E; Adler G
    Internist (Berl); 1993 Jan; 34(1):67-8. PubMed ID: 8440577
    [No Abstract]   [Full Text] [Related]  

  • 2. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications].
    Folwaczny C
    Z Gastroenterol; 2002 Dec; 40(12):991-8. PubMed ID: 12518265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombocytosis in ulcerative colitis and regional enteritis].
    Mohr P; Straub PW
    Schweiz Med Wochenschr; 1970 Jul; 100(27):1142-7. PubMed ID: 5524944
    [No Abstract]   [Full Text] [Related]  

  • 5. Peripheral blood T and B cells in chronic inflammatory bowel disease.
    Strickland RG; Korsmeyer S; Soltis RD; Wilson ID; Williams RC
    Gastroenterology; 1974 Oct; 67(4):569-77. PubMed ID: 4547268
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thromboembolic disease in patients with ulcerative colitis. Treatment and prevention].
    Carlsen E; Evensen SA
    Tidsskr Nor Laegeforen; 1983 Sep; 103(25):1759-61. PubMed ID: 6648912
    [No Abstract]   [Full Text] [Related]  

  • 7. [Decrease of antithrombin III and factor Xa inhibitor as the cause of thromboembolism complications in chronic inflammatory intestinal disease].
    Daiss W; Scheurlen M; Malchow H; Ostendorf P; Jaschonek K
    Internist (Berl); 1985 Oct; 26(10):643-5. PubMed ID: 3908368
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy of chronic inflammatory bowel diseases. Basic drug therapy].
    Riemann JF
    Verh Dtsch Ges Inn Med; 1988; 94():175-8. PubMed ID: 3061190
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events.
    Papa A; Danese S; Piccirillo N; Toriani-Terenzi C; Bartolozzi F; Piscaglia AC; Grillo A; Leone G; Gentiloni-Silveri N; Gasbarrini G; Gasbarrini A
    Hepatogastroenterology; 2003; 50(49):132-5. PubMed ID: 12630008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of chronic inflammatory bowel diseases. Long-term ambulatory care].
    Rohr G
    Verh Dtsch Ges Inn Med; 1988; 94():212-5. PubMed ID: 3144811
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of chronic inflammatory bowel diseases].
    Beglinger C
    Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcobalamin II level in peripheral blood monocytes--a biochemical marker in inflammatory diseases of the bowel.
    Rachmilewitz D; Ligumsky M; Rachmilewitz B; Rachmilewitz M; Tarcic N; Schlesinger M
    Gastroenterology; 1980 Jan; 78(1):43-6. PubMed ID: 7350034
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis.
    Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F
    Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease.
    Schottelius A; Wedel S; Weltrich R; Rohde W; Buttgereit F; Schreiber S; Lochs H
    Am J Gastroenterol; 2000 Aug; 95(8):1994-9. PubMed ID: 10950048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease.
    Glas J; Török HP; Daczo J; Tonenchi L; Folwaczny M; Folwaczny C
    Eur J Med Res; 2005 Dec; 10(12):535-8. PubMed ID: 16356870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease.
    Vespasiani Gentilucci U; Caviglia R; Picardi A; Carotti S; Ribolsi M; Galati G; Petitti T; Afeltra A; Cicala M
    Aliment Pharmacol Ther; 2005 May; 21(9):1063-71. PubMed ID: 15854167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease].
    Papo M; Quer JC; Pastor RM; García-Pardo G; Olona M; Prats E; Mirapeix E; Rodríguez R; Richart C
    Med Clin (Barc); 1998 Jan; 110(1):11-5. PubMed ID: 9527980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease.
    Sonoda K; Ikeda S; Mizuta Y; Miyahara Y; Kohno S
    J Gastroenterol; 2004 Oct; 39(10):948-54. PubMed ID: 15549447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.